trial · primary record
T-DXd
Advanced Cancer
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 75 |
| Primary completion | 2028-02-17 |
| Primary endpoint | Number of Participants Reporting Treatment-emergent Adverse Events Leading to Study Drug discontinuation and/or Dose Reduction, Treatment-emergent Serious Adverse Events (TESAEs), and Treatment-emergent Adverse Events of Special Interest (AESIs) |
| Registry ID | NCT06174987 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:20.506Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06174987
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.